SSG
CADL icon

Summit Securities Group’s Candel Therapeutics CADL Stock Holding History

Summit Securities Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03K Buy
+585
New +$4.42K ﹤0.01% 939

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Summit Securities Group's CADL Position: Q2 2026 in Review

Summit Securities Group opened a new position in Candel Therapeutics (CADL) in Q2 2026: 585 shares worth $6.03K. The stake represents ﹤0.01% of the portfolio and ranks #939 among its holdings.

138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Summit Securities Group held 585 shares of Candel Therapeutics worth $6.03K as of Q2 2026.
  • Candel Therapeutics was a new Summit Securities Group position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #939 holding.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.